Skip to main content
Premium Trial:

Request an Annual Quote

Jefferies Raises Revenue Expectations for Complete Genomics

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Jefferies has raised its revenue estimates for Complete Genomics for full-year 2011 and 2012, following the firm's presentation Friday morning at the Future Leaders in Biotech Industry Conference today in New York.

Jefferies analyst Jon Wood also raised his price target on the firm's stock to $15.50 from $13, and retained his "Buy" rating.

Complete Genomics CEO Clifford Reid said at the conference that the firm shipped 600 genomes to customers in the first quarter of 2011 — a 20 percent increase over estimates that it provided in mid-March. He also said that the company plans to open new facilities in Asia in 2013.

Reid also said that Complete Genomics currently has around 40 percent of the research market for whole-genome sequencing, which he estimated at about $50 million. By 2015, he said, that will jump to $900 million.

For 2011, Wood increased his revenue estimate for Complete Genomics to $36 million from an earlier estimate of $35 million. He upped his FY 2012 estimate to $80 million from $75 million.

He wrote that his forecast continues to assume that Complete Genomics will achieve positive gross margin in the second half of this year and operating income break-even in early 2013.

Shares of Complete Genomics jumped 15 percent in Friday trade on the Nasdaq to close at $13.44.


For more on Reid's presentation at the conference see GenomeWeb Daily News sister publication In Sequence.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.